. Author manuscript; available in PMC: 2021 Aug 15.

Published in final edited form as: Clin Cancer Res. 2020 Nov 30;27(4):983–991. doi: 10.1158/1078-0432.CCR-20-3089

Table 2.

Best Clinical Response

Response Type	Overall (n = 34)	1^st Line (n = 20)	2^nd Line (n = 14)
Complete response (CR), n (%)	3 (9)	2 (10)	1 (7)
Partial response (PR), n (%)	6(18)	4 (20)	2 (14)
Stable disease (SD), n (%)	13(38)	7 (35)	6 (43)
Progressive disease, n (%)	10 (29)	7 (35)	3 (21)
Not evaluable, n (%)	2 (6)	0 (0)	2 (14)
Overall response rate, % (95% CI)	26 (13–44)	30 (12–54)	21 (5–51)
Clinical benefit rate, % (95% CI)	32 (17–51)	30 (12–54)	36 (13–65)
Median PFS, months (95% CI)	4.9 (2.3–5.7)	3.8 (1.3–5.6)	5.0 (1.3–6.8)
Median OS, months (95% CI)	12.5 (7.5–14.9)	12.5 (9.7–14.0)	16.7 (2.3–24.4)

CI, confidence interval; Clinical benefit rate = CR + PR + SD ≥ 6 months; CR, clinical response; PR, partial response; SD, stable disease; PFS, progression-free survival; OS, overall survival